Examkin

Question

Difficulty: HardPsychopharmacology and Psychological Therapies

An individual with a well-documented history of bipolar I disorder is evaluated in the emergency department for altered mental status. According to family members, the patient has become progressively lethargic, confused, and unsteady on their feet over the past 48 hours. The patient has been taking divalproex sodium for several years with excellent mood control. Two weeks ago, a neurologist initiated topiramate for migraine prophylaxis. On examination, the patient is disoriented to time and place. When asked to hold their arms outstretched with wrists extended, a bilateral, non-rhythmic, flapping tremor is observed. Laboratory studies, including a complete blood count, aspartate aminotransferase, alanine aminotransferase, and total bilirubin, are all strictly within normal limits. Which of the following is the most likely cause of this patient's current presentation?

  1. Accumulation of ammonia due to urea cycle interferenceAnswer
  2. B
    Hepatocellular necrosis leading to hepatic encephalopathy
  3. C
    Synergistic enhancement of central GABAergic neurotransmission
  4. D
    Cytochrome P450-mediated toxic accumulation of divalproex
  5. E
    Serotonergic overstimulation of the central nervous system

Answer

The correct answer is the accumulation of ammonia due to urea cycle interference, commonly known as valproate-induced hyperammonemic encephalopathy.
The correct answer identifies the accumulation of ammonia due to interference with the urea cycle. Valproic acid can induce hyperammonemic encephalopathy by inhibiting carbamoyl phosphate synthetase I, the rate-limiting enzyme of the urea cycle. This risk is profoundly increased when topiramate is added. Topiramate acts as a carbonic anhydrase inhibitor, decreasing the availability of bicarbonate, which is an essential substrate for the urea cycle. This synergistic inhibition prevents the liver from clearing ammonia, leading to systemic hyperammonemia. The ammonia crosses the blood-brain barrier, causing metabolic encephalopathy characterized by lethargy, confusion, and the classic physical finding of asterixis. Crucially, this syndrome frequently occurs without any evidence of direct hepatocellular damage, meaning liver function tests (AST, ALT) often remain entirely normal.

Step-by-Step Solution

1
Analyze the patient's current medication list and recent changes.
The patient is on a chronic regimen of divalproex sodium and recently started topiramate.
Identifying recent medication additions is crucial for recognizing adverse drug interactions in psychiatric and neurologic pharmacotherapy.
2
Evaluate the clinical presentation and physical exam findings.
The patient presents with subacute altered mental status, lethargy, and asterixis (a flapping tremor).
Asterixis is a hallmark sign of a metabolic encephalopathy, specifically indicating the accumulation of toxic metabolic byproducts like ammonia in the brain.
3
Interpret the provided laboratory data.
Hepatic transaminases (AST, ALT) and bilirubin are completely normal.
Normal liver function tests rule out acute liver failure (hepatocellular necrosis) as the cause of the metabolic encephalopathy, narrowing the differential to non-hepatic causes of hyperammonemia.
4
Synthesize the mechanism linking the medications to the clinical presentation.
Valproate inhibits carbamoyl phosphate synthetase I in the urea cycle. Topiramate inhibits carbonic anhydrase, reducing bicarbonate (a necessary substrate for the urea cycle). Together, they cause a synergistic failure of ammonia clearance.
Understanding this specific pharmacological synergy explains the isolated hyperammonemia and resulting encephalopathy despite structurally intact liver tissue.

Key Concept

Valproate-induced hyperammonemic encephalopathy is a life-threatening complication characterized by altered mental status and asterixis with normal liver enzymes. The risk is significantly increased when valproate is co-administered with topiramate.
Rate this question

Topics

Psychopharmacology and Psychological Therapies

More questions from this topic